WEBVTT 00:00:00.000 --> 00:00:02.520 Welcome back to the Deep Dive. Today, we're tackling 00:00:02.520 --> 00:00:04.700 a challenge that, well, it's becoming increasingly 00:00:04.700 --> 00:00:07.179 common and certainly has a huge impact in orthopedic 00:00:07.179 --> 00:00:08.839 practice. We're talking about managing patients 00:00:08.839 --> 00:00:11.820 with advanced cancer, where bone pain and the 00:00:11.820 --> 00:00:13.779 risk of pathological fractures really come to 00:00:13.779 --> 00:00:15.740 the fore. And it's more than just treating a 00:00:15.740 --> 00:00:17.420 symptom, isn't it? It's about navigating this 00:00:17.420 --> 00:00:20.539 really complex sort of evolving landscape. Precision 00:00:20.539 --> 00:00:23.100 in diagnosis, in management, it's absolutely 00:00:23.100 --> 00:00:25.460 critical for us as mid -senior medical professionals. 00:00:25.859 --> 00:00:27.940 So our mission today is to really unpack the 00:00:27.940 --> 00:00:30.280 intricacies of metastatic bone disease, focusing 00:00:30.280 --> 00:00:32.740 on how it affects the limbs. We want to pull 00:00:32.740 --> 00:00:34.979 out those essential insights that directly shape 00:00:34.979 --> 00:00:37.219 patient care and, crucially, their quality of 00:00:37.219 --> 00:00:40.299 life. And guiding us through this challenging 00:00:40.299 --> 00:00:42.740 clinical terrain, we're incredibly fortunate 00:00:42.740 --> 00:00:45.539 to have Professor Mor Imam with us today. His 00:00:45.539 --> 00:00:47.840 expertise will really help eliminate these often 00:00:47.840 --> 00:00:50.140 quite daunting scenarios. Hashtag, tag, tag, 00:00:50.380 --> 00:00:51.859 understanding the landscape of bone metastasis. 00:00:52.649 --> 00:00:54.969 So just to set the scene, could you start by 00:00:54.969 --> 00:00:57.270 clarifying what exactly we mean by metastatic 00:00:57.270 --> 00:00:59.710 bone disease? How does it really differ from 00:00:59.710 --> 00:01:02.170 primary bone cancer? And why is that distinction 00:01:02.170 --> 00:01:04.689 just so important in clinical oncology today? 00:01:04.989 --> 00:01:07.030 Yes, absolutely. It's a crucial starting point. 00:01:07.629 --> 00:01:10.450 Metastatic bone cancer, or as we often call it, 00:01:10.590 --> 00:01:14.129 secondary bone cancer. Well, it describes tumors 00:01:14.129 --> 00:01:15.870 that start somewhere else in the body and other 00:01:15.870 --> 00:01:18.609 tissues or organs, and then they spread, they 00:01:18.609 --> 00:01:21.629 metastasize, to the bone. Right, so originating 00:01:21.629 --> 00:01:24.299 elsewhere. Exactly. And that's the key difference 00:01:24.299 --> 00:01:26.620 from primary bone cancer. Primary bone cancer 00:01:26.620 --> 00:01:29.319 actually develops from cancerous bone cells within 00:01:29.319 --> 00:01:32.280 the bone itself. It's a much, much rarer diagnosis, 00:01:32.519 --> 00:01:34.780 comparatively speaking. Now, the significance 00:01:34.780 --> 00:01:36.900 of metastatic bone disease really lies in its 00:01:36.900 --> 00:01:38.959 prevalence. The skeleton is, believe it or not, 00:01:39.140 --> 00:01:41.120 the third most common place for metastatic disease 00:01:41.120 --> 00:01:43.900 to land right after the lung and the liver. Third 00:01:43.900 --> 00:01:46.650 most common. Wow. Yes. And part of the reason 00:01:46.650 --> 00:01:49.329 is the bone's very rich arterial supply. It makes 00:01:49.329 --> 00:01:52.329 it, well, a very receptive environment for those 00:01:52.329 --> 00:01:54.209 tumor cells circulating in the blood after breaking 00:01:54.209 --> 00:01:56.650 off from the primary site. It's also vital to 00:01:56.650 --> 00:01:59.269 grasp that this isn't one single disease. It's 00:01:59.269 --> 00:02:02.549 a huge heterogeneous group. But despite the variety, 00:02:02.810 --> 00:02:05.370 they often do respond to different treatments. 00:02:05.870 --> 00:02:09.469 Chemotherapy, radiation, sometimes surgery. The 00:02:09.469 --> 00:02:12.520 overall goal always is to manage the significant 00:02:12.520 --> 00:02:15.060 clinical challenges it throws up, challenges 00:02:15.060 --> 00:02:18.199 that directly and often quite severely impact 00:02:18.199 --> 00:02:20.379 a patient's quality of life. That really clarifies 00:02:20.379 --> 00:02:22.460 it, common and impactful. So digging in a bit 00:02:22.460 --> 00:02:25.060 more, where do these secondary bone cancers typically 00:02:25.060 --> 00:02:27.520 come from, and what do the numbers tell us about 00:02:27.520 --> 00:02:30.159 incidence and maybe more starkly about patient 00:02:30.159 --> 00:02:32.710 survival? Well, historically, and it still holds 00:02:32.710 --> 00:02:35.090 true. The most common origin is carcinomas. So 00:02:35.090 --> 00:02:37.069 we most frequently see this coming from primary 00:02:37.069 --> 00:02:39.569 tumors in the breast, the lung, and the prostate. 00:02:39.750 --> 00:02:42.189 Those are the big three. But we are seeing more 00:02:42.189 --> 00:02:44.689 arising from renal cell carcinoma, that's kidney 00:02:44.689 --> 00:02:47.469 cancer, and also thyroid cancer. And they often 00:02:47.469 --> 00:02:49.110 have quite distinct patterns when they spread 00:02:49.110 --> 00:02:52.009 to bone. It's also worth mentioning non -epithelial 00:02:52.009 --> 00:02:54.870 cancers. Things like hematologic malignancies, 00:02:55.590 --> 00:02:58.020 multiple myeloma, lymphoma, they can... definitely 00:02:58.020 --> 00:03:01.219 involve bone, and sarcomas too, though they typically 00:03:01.219 --> 00:03:03.840 metastasize to bone quite late in the disease 00:03:03.840 --> 00:03:06.539 course. And the survival figures, I imagine they 00:03:06.539 --> 00:03:08.900 vary quite a bit. They vary dramatically, and 00:03:08.900 --> 00:03:10.580 that's critical when we're talking to patients. 00:03:11.039 --> 00:03:13.159 For instance, someone with lung cancer that spread 00:03:13.159 --> 00:03:15.840 to bone. Unfortunately, the median survival is 00:03:15.840 --> 00:03:18.319 typically around six to seven months. Oh, that's 00:03:18.319 --> 00:03:20.250 tough. It is. Compare that to breast cancer, 00:03:20.349 --> 00:03:22.669 where median survival might be 19 to 25 months, 00:03:22.710 --> 00:03:25.650 maybe a 20 % five -year survival. Prostate cancer 00:03:25.650 --> 00:03:28.449 has a wider range too, perhaps 12 to 53 months 00:03:28.449 --> 00:03:31.930 median survival, five -year survival around 25%. 00:03:31.930 --> 00:03:34.789 Myeloma, about 20 months median, 10 % of five 00:03:34.789 --> 00:03:37.250 years. Kidney cancer, often aggressive, maybe 00:03:37.250 --> 00:03:40.569 six months median, 10 % of five years. Thyroid 00:03:40.569 --> 00:03:43.349 cancer though, often slower growing, stands out 00:03:43.349 --> 00:03:46.189 48 months median survival, 40 % of five years. 00:03:46.270 --> 00:03:49.139 A huge difference there. Absolutely. And melanoma, 00:03:49.300 --> 00:03:51.060 again, often aggressive, about 6 months median, 00:03:51.439 --> 00:03:54.580 only 5 % surviving 5 years. So the variability 00:03:54.580 --> 00:03:57.449 is striking. In terms of overall incidence, one 00:03:57.449 --> 00:04:00.370 big U .S. study estimated about 2 .9 % cumulative 00:04:00.370 --> 00:04:03.889 incidence at 30 days, rising to 8 .4 % by 10 00:04:03.889 --> 00:04:06.669 years. Prostate cancer carries the highest risk, 00:04:06.830 --> 00:04:10.469 somewhere between 18 % and 29%, then lung, renal, 00:04:10.469 --> 00:04:12.409 breast. And clinically, how patients present 00:04:12.409 --> 00:04:14.969 also varies. It might be just a single bone lesion 00:04:14.969 --> 00:04:16.829 or what we call oligometastatic disease, just 00:04:16.829 --> 00:04:19.730 a few spots, or it could be multiple bone metastases 00:04:19.730 --> 00:04:22.329 or even metastases in bone plus other organs 00:04:22.329 --> 00:04:24.850 like the liver or lungs. This variety really 00:04:24.720 --> 00:04:26.600 underlines why we need a tailored approach for 00:04:26.600 --> 00:04:28.920 each patient. Hashtag tag tag the mechanisms 00:04:28.920 --> 00:04:30.920 of spread and bone damage. It is quite remarkable 00:04:30.920 --> 00:04:33.399 how these cancers, starting so far away, find 00:04:33.399 --> 00:04:35.879 their way to bone. What is it about bone specifically 00:04:35.879 --> 00:04:37.920 that makes it such a, well, receptive spot? And 00:04:37.920 --> 00:04:39.540 can you walk us through the actual mechanisms 00:04:39.540 --> 00:04:41.600 of how they spread? It is remarkable, you're 00:04:41.600 --> 00:04:43.600 right. And the process is often explained by 00:04:43.600 --> 00:04:45.980 this concept called the seed and soil hypothesis. 00:04:46.980 --> 00:04:49.740 Basically, successful metastasis isn't just random 00:04:49.740 --> 00:04:52.269 chance. It depends on the specific characteristics 00:04:52.269 --> 00:04:55.170 of the tumor cell, the seed, and a very receptive 00:04:55.170 --> 00:04:58.850 microenvironment in the bone, the soil. The main 00:04:58.850 --> 00:05:01.829 way they get there, overwhelmingly, it's hematogenous 00:05:01.829 --> 00:05:04.990 spread through the bloodstream. Although, you 00:05:04.990 --> 00:05:07.589 can also get local invasion, where a soft tissue 00:05:07.589 --> 00:05:09.850 tumor nearby just goes directly into the adjacent 00:05:09.850 --> 00:05:13.069 bone. Now, if we look at spinal metastasis specifically, 00:05:13.769 --> 00:05:15.670 spread via the venous system is really dominant. 00:05:15.819 --> 00:05:17.779 Think about lung and breast cancer. They often 00:05:17.779 --> 00:05:20.540 go to the thoracic spine. Why? Because of their 00:05:20.540 --> 00:05:23.120 venous drainage. Breast cancer drains via the 00:05:23.120 --> 00:05:25.920 ozygous vein, which talks directly to Batson's 00:05:25.920 --> 00:05:28.420 plexus in the spine, a network of veins without 00:05:28.420 --> 00:05:31.759 valves. I have a direct route. Exactly. And similarly, 00:05:32.000 --> 00:05:34.120 prostate cancer often goes to the lumbar sacral 00:05:34.120 --> 00:05:36.439 spine and pelvis because its drainage is via 00:05:36.439 --> 00:05:39.379 the pelvic plexus there. It's anatomy facilitating 00:05:39.379 --> 00:05:42.180 the spread. Interestingly, lung and renal cancer 00:05:42.180 --> 00:05:44.899 can sometimes spread way out to the distal extremities, 00:05:45.060 --> 00:05:48.300 hands, feet. That's often thought to be via the 00:05:48.300 --> 00:05:50.660 arterial tree, indicating more widespread systemic 00:05:50.660 --> 00:05:53.860 seeding. But coming back to seed and soil, once 00:05:53.860 --> 00:05:55.579 those tumor cells arrive in the bone marrow, 00:05:56.220 --> 00:05:58.500 really complex interactions happen. Tumor cell 00:05:58.500 --> 00:06:02.980 receptors Things like CXCR4 and Aran -KL, they 00:06:02.980 --> 00:06:05.160 interact with the bone marrow stromal cells and 00:06:05.160 --> 00:06:07.220 the bone matrix itself. And that interaction 00:06:07.220 --> 00:06:09.379 is key. Absolutely pivotal, because it triggers 00:06:09.379 --> 00:06:11.600 a whole cascade. It leads to the release of growth 00:06:11.600 --> 00:06:13.639 factors, cytokines, things like interleukin 6, 00:06:13.740 --> 00:06:15.800 interleukin 8, and factors that promote blood 00:06:15.800 --> 00:06:18.220 vessel growth, like VEGF. So the cancer cells 00:06:18.220 --> 00:06:20.600 are manipulating the local environment. Precisely. 00:06:20.920 --> 00:06:23.860 This biochemical soup drives tumor growth. But 00:06:23.860 --> 00:06:27.470 critically, it also activates osteoclasts. the 00:06:27.470 --> 00:06:30.230 cells that break down bone leading to osteolysis, 00:06:30.569 --> 00:06:33.529 the destruction of bone. So the cancer cells 00:06:33.529 --> 00:06:35.829 effectively hijack the bone's own regulatory 00:06:35.829 --> 00:06:38.250 systems to create an environment that helps them 00:06:38.250 --> 00:06:41.189 thrive and spread. They coerce the bone into 00:06:41.189 --> 00:06:43.189 supporting their own destructive agenda, in a 00:06:43.189 --> 00:06:46.069 way. That's quite an insidious mechanism actively 00:06:46.069 --> 00:06:49.509 manipulating the bone. So given this manipulation, 00:06:50.149 --> 00:06:52.589 how do the metastatic cells actually impact the 00:06:52.589 --> 00:06:54.970 bone structure itself? Do they manifest differently? 00:06:55.290 --> 00:06:57.769 And what are the cellular processes driving this 00:06:57.769 --> 00:06:59.670 destruction or maybe sometimes, surprisingly, 00:07:00.050 --> 00:07:02.870 new bone formation? That's exactly right. They're 00:07:02.870 --> 00:07:04.910 active players. And when we look at imaging, 00:07:05.189 --> 00:07:07.209 we broadly classify how they affect the bone 00:07:07.209 --> 00:07:09.769 into three main types based on appearance and 00:07:09.769 --> 00:07:12.370 the underlying cellular chaos they cause. First, 00:07:12.509 --> 00:07:15.009 you have osteoblastic lesions, also called sclerotic. 00:07:15.120 --> 00:07:17.160 These are characterized by new bone formation, 00:07:17.259 --> 00:07:19.420 although it's often disorganized. You see this 00:07:19.420 --> 00:07:21.779 most classically in prostate cancer. About 90 00:07:21.779 --> 00:07:24.519 % of prostate mets are blastic. Breast cancer 00:07:24.519 --> 00:07:26.879 can also show blastic features, maybe 60 % of 00:07:26.879 --> 00:07:29.360 the time. So they actually make bone grow. In 00:07:29.360 --> 00:07:32.379 a way, yes. The tumor cells secrete a molecule 00:07:32.379 --> 00:07:36.259 called endothelin 1, ET1. This binds to receptors 00:07:36.259 --> 00:07:40.040 on osteoblasts, the bone building cells, stimulating 00:07:40.040 --> 00:07:42.920 them, and activating pathways like the WNT pathway, 00:07:43.040 --> 00:07:45.560 it promotes new bone formation. It's almost like 00:07:45.560 --> 00:07:47.620 the tumor is tricking the bone into building 00:07:47.620 --> 00:07:50.339 a scaffold around it. Second, we have osteolytic 00:07:50.339 --> 00:07:52.399 lesions. These are all about bone destruction, 00:07:52.759 --> 00:07:55.139 very common in breast, lung, and renal cancers. 00:07:55.339 --> 00:07:58.120 In fact, lung, thyroid, and renal mets are predominantly 00:07:58.120 --> 00:08:00.699 etolytic. On imaging, you see thinning of the 00:08:00.699 --> 00:08:03.220 bone's internal structure, the trabeculae, often 00:08:03.220 --> 00:08:05.660 with fuzzy, ill -defined margins. It looks like 00:08:05.660 --> 00:08:08.389 the bone is being eaten away. And thirdly, you 00:08:08.389 --> 00:08:10.769 get mixed lesions, showing features of both destruction 00:08:10.769 --> 00:08:13.149 and new formation. You see this frequently in 00:08:13.149 --> 00:08:15.250 breast cancer, highlighting its complex interaction 00:08:15.250 --> 00:08:17.769 with bone. Okay. And you mentioned osteolytic 00:08:17.769 --> 00:08:20.110 lesions destruction. What's driving that specifically? 00:08:20.410 --> 00:08:22.629 Ah yes, this is where we get into what's called 00:08:22.629 --> 00:08:24.350 the vicious circle of bone destruction. It's 00:08:24.350 --> 00:08:27.050 a really key concept. It starts with tumor cells 00:08:27.050 --> 00:08:30.009 secreting a protein called PTHRP, parathyroid 00:08:30.009 --> 00:08:33.909 hormone related protein. This PTHRP stimulates 00:08:33.909 --> 00:08:36.330 osteoblasts to release another key molecule, 00:08:36.809 --> 00:08:40.450 NKL. NKL then binds to its receptor, rank, which 00:08:40.450 --> 00:08:43.990 sits on osteoclast precursors. This binding signals 00:08:43.990 --> 00:08:46.950 these precursors to mature into active osteoclasts, 00:08:47.129 --> 00:08:49.250 the bone destroyers. Right, the cells that break 00:08:49.250 --> 00:08:52.169 down bones. Exactly. So these activated osteoclasts 00:08:52.169 --> 00:08:54.850 get to work, causing significant bone resorption, 00:08:55.230 --> 00:08:56.909 breaking down the bone matrix. But here's the 00:08:56.909 --> 00:08:59.429 vicious part. As the bone breaks down, it releases 00:08:59.429 --> 00:09:01.549 growth factors stored within it, things like 00:09:01.549 --> 00:09:05.379 TGF beta, ILGF -1, and calcium. These released 00:09:05.379 --> 00:09:07.620 factors then feed back and stimulate the tumor 00:09:07.620 --> 00:09:11.200 cells to produce even more PTHRP. Ah, so it literally 00:09:11.200 --> 00:09:14.519 feeds itself a cycle. Precisely. It perpetuates 00:09:14.519 --> 00:09:16.279 and accelerates the cycle of bone destruction 00:09:16.279 --> 00:09:18.940 and tumor growth. Plus, other pro -inflammatory 00:09:18.940 --> 00:09:22.360 cytokines like IL -6 and IL -8 and VEGF also 00:09:22.360 --> 00:09:24.620 contribute further fueling the fire. It's a really 00:09:24.620 --> 00:09:26.970 destructive feedback loop. That vicious circle 00:09:26.970 --> 00:09:29.509 sounds incredibly damaging and you can see how 00:09:29.509 --> 00:09:33.649 it leads to so much pathology. So with this destructive 00:09:33.649 --> 00:09:36.169 process happening at the cellular level, how 00:09:36.169 --> 00:09:38.210 does it actually show up in a patient's life? 00:09:38.730 --> 00:09:41.450 What are the key clinical signs, those red flags, 00:09:41.730 --> 00:09:43.690 that should really make us think about metastatic 00:09:43.690 --> 00:09:46.850 bone disease? And what are the critical skeletal 00:09:46.850 --> 00:09:50.110 -related events, SREs, that we absolutely need 00:09:50.110 --> 00:09:52.519 to be watching out for? Well, the most common 00:09:52.519 --> 00:09:54.879 way patients present is almost always with progressive 00:09:54.879 --> 00:09:57.500 pain or the development of one of these skeletal 00:09:57.500 --> 00:09:59.919 -related events, SREs for short. It's actually 00:09:59.919 --> 00:10:01.539 quite common for patients, especially if they're 00:10:01.539 --> 00:10:03.960 still active, to initially blame the symptoms 00:10:03.960 --> 00:10:06.740 on some unrelated knock or a low energy injury. 00:10:06.940 --> 00:10:09.120 Oh, I must have just pulled something. Irrationalize 00:10:09.120 --> 00:10:12.759 it. Exactly. But a classic red flag for us is 00:10:12.759 --> 00:10:15.320 pain that just doesn't go away, maybe even gets 00:10:15.320 --> 00:10:19.019 worse, despite standard painkillers. That suggests 00:10:19.019 --> 00:10:21.679 something more serious is going on. A thorough 00:10:21.679 --> 00:10:24.000 history and physical exam are absolutely vital 00:10:24.000 --> 00:10:26.799 for spotting specific red flags. We're looking 00:10:26.799 --> 00:10:28.679 for things like night pain, often described as 00:10:28.679 --> 00:10:32.259 this dull, boring ache, comes on gradually, characteristically 00:10:32.259 --> 00:10:35.470 worse at night, sometimes waking them up. It 00:10:35.470 --> 00:10:37.750 is. Unintentional weight loss is another big 00:10:37.750 --> 00:10:40.350 one. Pain, specifically with weight bearing, 00:10:40.669 --> 00:10:43.090 especially if it's new or worsening, is very 00:10:43.090 --> 00:10:45.490 concerning for mechanical instability. And of 00:10:45.490 --> 00:10:47.549 course, finding and enlarging mass in the area 00:10:47.549 --> 00:10:50.389 is a direct sign needing urgent investigation. 00:10:51.190 --> 00:10:52.830 Clinicians should look carefully at the skin 00:10:52.830 --> 00:10:56.149 over the area any sweating, tenderness on palpation, 00:10:56.730 --> 00:10:59.779 open wounds, even dimpling. And if you suspect 00:10:59.779 --> 00:11:01.779 an impending fracture or they've had an injury, 00:11:02.480 --> 00:11:04.820 initial immobilization with a simple splint can 00:11:04.820 --> 00:11:07.970 be crucial to stop a fracture propagating. Where 00:11:07.970 --> 00:11:09.750 does it usually happen? The vertebrae are by 00:11:09.750 --> 00:11:12.269 far the most common site. After that, the femur, 00:11:12.509 --> 00:11:14.750 pelvis, ribs, sternum, the top of the humerus, 00:11:14.990 --> 00:11:17.470 and the skull. This distribution often dictates 00:11:17.470 --> 00:11:19.590 the kind of SREs we see. Right, so what are those 00:11:19.590 --> 00:11:22.009 key SREs? Right, the skeletal -related events. 00:11:22.529 --> 00:11:24.649 These are the major problems that arise directly 00:11:24.649 --> 00:11:27.649 from the bone architecture being destroyed. First, 00:11:28.110 --> 00:11:30.070 as I said, bone pain, most frequent symptom. 00:11:30.240 --> 00:11:32.539 It can be mechanical pain from weakened bone 00:11:32.539 --> 00:11:35.299 moving or tuberogenic pain from the tumor itself, 00:11:35.639 --> 00:11:38.419 irritating nerves or stretching the periosteum. 00:11:39.019 --> 00:11:41.480 Next, and this is a huge concern due to a potential 00:11:41.480 --> 00:11:44.179 permanent disability, is nerve root or spinal 00:11:44.179 --> 00:11:46.360 cord compression. Because the spine is the most 00:11:46.360 --> 00:11:48.820 common site, this is a really serious complication. 00:11:49.019 --> 00:11:51.500 It's an orthopedic emergency. An emergency. Absolutely. 00:11:52.039 --> 00:11:53.740 Yeah. Nerve root compression might just cause 00:11:53.740 --> 00:11:56.620 a ridiculous pain, that sharp shooting pain down 00:11:56.620 --> 00:11:59.570 an arm or leg. But spinal cord compression. that 00:11:59.570 --> 00:12:01.870 often starts with back pain, then progresses 00:12:01.870 --> 00:12:03.990 to ling weakness, the second most common symptom. 00:12:04.370 --> 00:12:06.909 You can get sensory changes too, numbness, tingling 00:12:06.909 --> 00:12:10.029 below the level. Late signs are autonomic dysfunction, 00:12:10.450 --> 00:12:13.269 bowel, bladder problems, impotence, that's critical. 00:12:13.690 --> 00:12:15.909 Early recognition, quick workup, urgent surgical 00:12:15.909 --> 00:12:18.210 consultation, they're vital to prevent potentially 00:12:18.210 --> 00:12:20.730 devastating permanent neurological damage like 00:12:20.730 --> 00:12:23.330 paralysis. Then there's hypercalitemia, high 00:12:23.330 --> 00:12:25.350 calcium levels in the blood. occurs in maybe 00:12:25.350 --> 00:12:28.289 10 -30 % of cases with osteolectic mats. And 00:12:28.289 --> 00:12:30.529 unfortunately, it usually signals a poor prognosis 00:12:30.529 --> 00:12:32.850 overall. It's mainly driven by that excessive 00:12:32.850 --> 00:12:36.450 osteoclast activity stimulated by PTHRP releasing 00:12:36.450 --> 00:12:38.110 too much calcium from the bone. And how does 00:12:38.110 --> 00:12:40.970 that present? Symptoms can be vague nausea, poor 00:12:40.970 --> 00:12:43.809 appetite, abdominal pain, constipation, changes 00:12:43.809 --> 00:12:46.169 in mental state like confusion or lethargy, even 00:12:46.169 --> 00:12:48.929 coma. It needs immediate hospital admission and 00:12:48.929 --> 00:12:52.029 IV fluids to bring the calcium down. Pathological 00:12:52.029 --> 00:12:54.789 fractures are another major SRE. The weakened 00:12:54.789 --> 00:12:57.610 bone breaks with minimal or no trauma. Constant 00:12:57.610 --> 00:13:00.090 pain is typical beforehand. Spinal fractures 00:13:00.090 --> 00:13:02.929 are often worse sitting or standing. These fractures 00:13:02.929 --> 00:13:05.590 cause huge problems, severe pain, nerve issues 00:13:05.590 --> 00:13:08.429 like sciatica, the pelvis fractures, deformities, 00:13:08.649 --> 00:13:11.029 immobility. They happen at presentation in maybe 00:13:11.029 --> 00:13:14.309 8 -30 % of patients and crucially, 90 % of them 00:13:14.309 --> 00:13:16.389 need surgery. They almost never heal on their 00:13:16.389 --> 00:13:18.389 own. They don't heal. That's critical for planning. 00:13:18.629 --> 00:13:20.710 Absolutely. We can't rely on biology to fix it. 00:13:20.909 --> 00:13:23.399 And finally, myelophysis. That's symptomatic 00:13:23.399 --> 00:13:25.320 anemia because the metastatic cells infiltrate 00:13:25.320 --> 00:13:27.340 the bone marrow and crowd out the normal blood 00:13:27.340 --> 00:13:30.399 -forming cells. In late stages, you can get pancetopenia 00:13:30.399 --> 00:13:33.200 low levels of all blood cells. All these SREs 00:13:33.200 --> 00:13:35.059 just devastate a patient's quality of life and 00:13:35.059 --> 00:13:37.200 independence, which is why catching things early 00:13:37.200 --> 00:13:39.340 and intervening thoughtfully is so incredibly 00:13:39.340 --> 00:13:42.059 important. That's a really clear picture of the 00:13:42.059 --> 00:13:44.600 clinical impact and just how devastating SREs 00:13:44.600 --> 00:13:47.059 can be. So given all these symptoms and potential 00:13:47.059 --> 00:13:49.820 complications, how crucial is getting an early 00:13:49.820 --> 00:13:52.559 diagnosis? And what are the sort of standard 00:13:52.559 --> 00:13:55.059 pathways and tools we use to confirm metastatic 00:13:55.059 --> 00:13:56.720 bone disease, especially if we don't know where 00:13:56.720 --> 00:13:59.600 the primary cancer is? Early identification is 00:13:59.600 --> 00:14:02.139 absolutely paramount. It's not just for accurate 00:14:02.139 --> 00:14:04.419 staging or predicting prognosis, though that's 00:14:04.419 --> 00:14:07.159 important. It's mainly for getting timely prophylactic 00:14:07.159 --> 00:14:09.960 measures and treatments in place. Doing that 00:14:09.960 --> 00:14:12.940 early can significantly reduce morbidity, prevent 00:14:12.940 --> 00:14:16.080 those awful SREs, and often extend a patient's 00:14:16.080 --> 00:14:19.019 functional life, their quality time. The approach 00:14:19.019 --> 00:14:21.460 really demands a complete workup before any major 00:14:21.460 --> 00:14:24.139 intervention, especially if someone presents 00:14:24.139 --> 00:14:26.940 with a pathological fracture. Because remember, 00:14:27.340 --> 00:14:29.299 that bone metastasis might be the very first 00:14:29.299 --> 00:14:31.659 sign of an unknown primary cancer. We see that 00:14:31.659 --> 00:14:33.980 quite often. Or it could be in someone with a 00:14:33.980 --> 00:14:36.860 known cancer history. So if the primary is unknown, 00:14:37.039 --> 00:14:39.120 or if the patient has a history of multiple different 00:14:39.120 --> 00:14:42.779 cancers, a biopsy is essential. Absolutely essential. 00:14:43.100 --> 00:14:44.679 Before we even think about planning surgery, 00:14:44.840 --> 00:14:47.159 it's a fundamental rule. Don't operate on a bone 00:14:47.159 --> 00:14:49.080 lesion without knowing what it is through a tissue 00:14:49.080 --> 00:14:51.730 diagnosis. That makes perfect sense, biopsy first. 00:14:52.250 --> 00:14:55.210 So once we suspect metastatic disease, what are 00:14:55.210 --> 00:14:57.190 the main imaging tools we reach for? Can you 00:14:57.190 --> 00:14:58.610 walk us through the strengths and weaknesses 00:14:58.610 --> 00:15:01.570 of each one, from simple x -rays up to the more 00:15:01.570 --> 00:15:04.929 advanced nuclear medicine scans? Certainly. Each 00:15:04.929 --> 00:15:06.429 one gives us a different piece of the puzzle, 00:15:06.570 --> 00:15:08.370 and we often use them together to build the full 00:15:08.370 --> 00:15:11.169 picture. Plane radiographs' x -rays are usually 00:15:11.169 --> 00:15:13.250 the first step for someone with focal bone pain. 00:15:13.470 --> 00:15:15.370 We use them to check out suspicious areas seen 00:15:15.370 --> 00:15:17.950 on a bone scan or to look for obvious fractures. 00:15:18.090 --> 00:15:20.870 They're best at seeing osteolytic lesions, the 00:15:20.870 --> 00:15:23.929 destructive ones. But here's the catch. A lesion 00:15:23.929 --> 00:15:26.509 often needs to be quite large, maybe over a centimeter 00:15:26.509 --> 00:15:29.509 or two, and have destroyed over 50 % of the bone 00:15:29.509 --> 00:15:32.090 mineral content before it even shows up clearly 00:15:32.090 --> 00:15:34.509 on an x -ray. So a normal x -ray doesn't rule 00:15:34.509 --> 00:15:37.409 it out then? Not at all. Lytic lesions look like 00:15:37.409 --> 00:15:39.730 areas of decreased density, maybe fuzzy edges. 00:15:40.190 --> 00:15:43.539 Slerotic lesions look denser. more nodular. X 00:15:43.539 --> 00:15:45.639 -rays can help monitor progression or healing. 00:15:46.279 --> 00:15:48.679 Seeing sclerosis increase can be a sign of response 00:15:48.679 --> 00:15:50.980 to treatment, but their main weakness is poor 00:15:50.980 --> 00:15:54.000 sensitivity for early or subtle disease. Computed 00:15:54.000 --> 00:15:56.860 tomography, or CT, is much more sensitive than 00:15:56.860 --> 00:15:59.480 x -ray, maybe around 74%. It gives excellent 00:15:59.480 --> 00:16:01.600 detail of both the cortical shell and the internal 00:16:01.600 --> 00:16:04.200 trabecular bone. Great for seeing both inoculitic 00:16:04.200 --> 00:16:06.059 and blastic lesions. What are the advantages 00:16:06.059 --> 00:16:09.110 of CT? Several. It can help with staging cancer 00:16:09.110 --> 00:16:11.429 elsewhere in the body at the same time. It lets 00:16:11.429 --> 00:16:14.629 us objectively measure bone density changes using 00:16:14.629 --> 00:16:16.730 Houndsfield units, which helps assess response. 00:16:17.250 --> 00:16:20.389 Ribs are much better seen on CT. And it's incredibly 00:16:20.389 --> 00:16:22.750 useful for preoperative planning, especially 00:16:22.750 --> 00:16:24.789 in tricky areas like the shoulder or pelvis. 00:16:25.070 --> 00:16:27.269 We can get 3D reconstructions to guide surgery. 00:16:27.889 --> 00:16:30.549 Magnetic Resonance Imaging, MRI, is really the 00:16:30.549 --> 00:16:32.289 gold standard for looking at soft tissues in 00:16:32.289 --> 00:16:34.590 bone marrow. It has very high sensitivity, around 00:16:34.590 --> 00:16:38.350 95%, and specificity, maybe 90%, for detecting 00:16:38.350 --> 00:16:40.549 bone myths. Better than a bone scan for early 00:16:40.549 --> 00:16:43.570 detection. Yes. A key advantage is it can detect 00:16:43.570 --> 00:16:45.289 marrow involvement before the bone structure 00:16:45.289 --> 00:16:47.730 itself changes enough to be seen as a blastic 00:16:47.730 --> 00:16:51.279 lesion. So it picks up disease earlier. It's 00:16:51.279 --> 00:16:53.700 also safe in pregnancy and absolutely crucial 00:16:53.700 --> 00:16:56.100 for assessing suspected spinal cord compression. 00:16:56.779 --> 00:16:58.980 It shows the relationship between the tumor and 00:16:58.980 --> 00:17:01.879 the nerves perfectly. Metastases typically look 00:17:01.879 --> 00:17:04.640 dark on T1 -weighted images, replacing the bright 00:17:04.640 --> 00:17:07.339 fatty marrow and bright on T2 -weighted images, 00:17:07.539 --> 00:17:09.579 indicating water content like oedema or tumor 00:17:09.579 --> 00:17:12.180 cells. Whole -body MRI is also becoming more 00:17:12.180 --> 00:17:13.859 common, highly accurate for early detection, 00:17:14.059 --> 00:17:16.420 especially in areas rich in red marrow like the 00:17:16.420 --> 00:17:19.519 spine and pelvis. Then we move to nuclear medicine 00:17:19.519 --> 00:17:22.119 scans. These use radioactive tracers that are 00:17:22.119 --> 00:17:24.539 taken up by bone. The skeletal scintigraphy, 00:17:24.640 --> 00:17:27.299 or bone scan, using Technetium 99 -meter MDP, 00:17:27.740 --> 00:17:30.140 is the workhorse. Scans the whole skeleton, very 00:17:30.140 --> 00:17:33.440 sensitive, maybe 78 % for early diagnosis. It's 00:17:33.440 --> 00:17:35.599 great at detecting osteoblastic activity areas 00:17:35.599 --> 00:17:37.759 of increased bone turnover show up as hot spots. 00:17:37.859 --> 00:17:41.059 But it has downsides. Big ones. Low specificity. 00:17:41.579 --> 00:17:44.140 A hot spot could be arthritis, infection, a healing 00:17:44.140 --> 00:17:46.609 fracture, anything causing bone turnover. I can't 00:17:46.609 --> 00:17:49.589 reliably distinguish benign from malignant. And 00:17:49.589 --> 00:17:51.890 it's notoriously poor for purely lytic lesions, 00:17:52.109 --> 00:17:53.710 because there's no increased bone formation to 00:17:53.710 --> 00:17:56.170 pick up the tracer. Myeloma lesions, for example, 00:17:56.230 --> 00:17:59.009 are often cold on a bone scan. Spect imaging, 00:17:59.250 --> 00:18:02.730 also using TC99 -medin -MDP, gives us cross -sectional 00:18:02.730 --> 00:18:05.609 images, like CT. This provides better anatomical 00:18:05.609 --> 00:18:07.630 localization and improves specificity to around 00:18:07.630 --> 00:18:11.109 91 % compared to the planar bone scan. PE scans, 00:18:11.410 --> 00:18:13.970 using tracers like 18F -FDG, glucose analog, 00:18:14.269 --> 00:18:17.269 or 18F -sodium fluorine, NAF, reflex bone production, 00:18:17.670 --> 00:18:20.349 identify METs based on metabolic activity. PD 00:18:20.349 --> 00:18:22.089 generally has better spatial resolution than 00:18:22.089 --> 00:18:25.190 bone scans or SPECT. 18F -NAF -PET, in particular, 00:18:25.269 --> 00:18:27.269 has shown substantially better sensitivity and 00:18:27.269 --> 00:18:29.809 specificity than bone scan and SPECT. It's a 00:18:29.809 --> 00:18:31.910 very powerful tool. And finally, we have hybrid 00:18:31.910 --> 00:18:34.349 imaging. Combining modalities is key. For example, 00:18:34.369 --> 00:18:37.009 18F -NAF -PET -CT fuses the metabolic information 00:18:37.009 --> 00:18:39.769 from PD with the anatomical detail from CT. It 00:18:39.769 --> 00:18:42.210 gives fantastic sensitivity close to 100 % and 00:18:42.210 --> 00:18:44.569 specificity around 97%. You see exactly where 00:18:44.569 --> 00:18:46.609 the metabolic activity is located. Other useful 00:18:46.609 --> 00:18:50.730 hybrids include Spexiti, Petziti, and even PDMRI. 00:18:51.970 --> 00:18:53.750 They all help give us the most complete picture 00:18:53.750 --> 00:18:56.549 to guide diagnosis and treatment. That's a fantastic 00:18:56.549 --> 00:18:58.630 run -through of the imaging toolkit. It really 00:18:58.630 --> 00:19:00.529 shows how layering these techniques gives us 00:19:00.529 --> 00:19:02.990 a clearer picture. Beyond the scans, what about 00:19:02.990 --> 00:19:05.829 lab tests? What blood work helps in the diagnosis? 00:19:06.329 --> 00:19:09.289 And crucially, when is that biopsy absolutely 00:19:09.289 --> 00:19:11.250 essential, especially when the primary cancer 00:19:11.250 --> 00:19:14.210 isn't known? Lab investigations definitely play 00:19:14.210 --> 00:19:16.589 a valuable supporting role, giving us systemic 00:19:16.589 --> 00:19:19.710 clues. Routine bloods like a complete blood count, 00:19:19.930 --> 00:19:22.670 CBC, and a comprehensive metabolic panel are 00:19:22.670 --> 00:19:26.269 standard. The CBC might show anemia, low platelets, 00:19:26.430 --> 00:19:28.690 or even pancytopenia in late -stage disease, 00:19:29.150 --> 00:19:31.150 indicating significant marrow involvement, often 00:19:31.150 --> 00:19:34.769 a poor sign. Serum calcium and alkaline phosphatase 00:19:34.769 --> 00:19:36.650 can be elevated because of the bone destruction, 00:19:37.089 --> 00:19:39.730 the osteolysis. While specific bone turnover 00:19:39.730 --> 00:19:42.170 markers are still researched, things like tartrate 00:19:42.170 --> 00:19:44.390 -resistant acid phosphatase can be high in breast 00:19:44.390 --> 00:19:46.390 and prostate cancer mats. Are there specific 00:19:46.390 --> 00:19:48.930 tumor markers, too? Yes, depending on what primary 00:19:48.930 --> 00:19:53.400 we suspect. Reject PSA for prostate, CA125 for 00:19:53.400 --> 00:19:57.619 ovarian, CA19 .9 for pancreatic biliary, calcitonin 00:19:57.619 --> 00:20:00.579 for medullary thyroid cancer, CEA for colorectal 00:20:00.579 --> 00:20:03.740 or breast, plus thyroid function tests. And it's 00:20:03.740 --> 00:20:05.420 really important to screen for multiple myeloma, 00:20:05.460 --> 00:20:07.759 which can look very similar. So we do serum and 00:20:07.759 --> 00:20:10.359 urine protein electrophoresis, SBEP, UPEP, beta 00:20:10.359 --> 00:20:13.440 -2 microglobulin, C -reactive protein. Even simple 00:20:13.440 --> 00:20:15.799 urinalysis might show blood pointing towards 00:20:15.799 --> 00:20:18.490 the kidney primary. Now, the biopsy. This is 00:20:18.490 --> 00:20:19.990 often where we get the definitive answer, and 00:20:19.990 --> 00:20:22.029 it's absolutely critical. You must get tissue 00:20:22.029 --> 00:20:24.329 confirmation if the patient has an unknown primary 00:20:24.329 --> 00:20:26.849 cancer or if they have a known cancer history 00:20:26.849 --> 00:20:30.289 but haven't had bone meds before. We also strongly 00:20:30.289 --> 00:20:32.130 consider it if someone has a history of multiple 00:20:32.130 --> 00:20:34.490 different cancers. We need to know which cancer 00:20:34.490 --> 00:20:36.470 has spread to the bone to guide the right systemic 00:20:36.470 --> 00:20:38.490 treatment. And what does the biopsy tell us? 00:20:38.710 --> 00:20:41.160 The histopathology. Under the microscope might 00:20:41.160 --> 00:20:43.519 show characteristic features like epithelial 00:20:43.519 --> 00:20:46.119 cells clumped together. Then we use immunostaining 00:20:46.119 --> 00:20:49.119 special stains like keratin, CK7 for breast lung, 00:20:49.619 --> 00:20:52.500 TTF1 for lung to help pinpoint the origin. For 00:20:52.500 --> 00:20:54.519 breast cancer, checking the hormone receptor 00:20:54.519 --> 00:20:58.000 status ER, PR, retinue is essential for guiding 00:20:58.000 --> 00:21:01.160 medical therapy. Imaging, as we discussed, helps 00:21:01.160 --> 00:21:03.799 us pick the best, safest spot for the biopsy 00:21:03.799 --> 00:21:06.400 or guides a needle biopsy accurately. But the 00:21:06.400 --> 00:21:08.299 bottom line, I can't stress it enough, is you 00:21:08.299 --> 00:21:10.460 should not proceed with major surgery on a bone 00:21:10.460 --> 00:21:13.700 lesion without a tissue diagnosis first. It prevents 00:21:13.700 --> 00:21:16.519 mismanaging something else entirely. Such a crucial 00:21:16.519 --> 00:21:19.119 point, tissue, is the issue. So with all these 00:21:19.119 --> 00:21:21.180 diagnostic tools, what other conditions might 00:21:21.180 --> 00:21:23.660 look like bone metastasis? What's the thought 00:21:23.660 --> 00:21:25.519 process for telling them apart, especially when 00:21:25.519 --> 00:21:27.359 things aren't straightforward? That's a really 00:21:27.359 --> 00:21:29.839 important question because the differential diagnosis 00:21:29.839 --> 00:21:32.519 can be quite wide, and it often depends on the 00:21:32.519 --> 00:21:34.680 specific bone involved and the patient's history. 00:21:34.960 --> 00:21:37.640 But the main things we need to rule out include 00:21:37.640 --> 00:21:40.299 primary bone sarcoma, totally different treatment, 00:21:40.900 --> 00:21:42.720 multiple myeloma of the blood cancer causing 00:21:42.720 --> 00:21:45.880 lytic lesions, primary malignant lymphoma bone. 00:21:46.410 --> 00:21:48.890 even secondary sarcoma that can arise after radiation 00:21:48.890 --> 00:21:51.329 treatment years later. And non -cancerous things. 00:21:51.569 --> 00:21:54.009 Absolutely. Osteomyelitis bone infection can 00:21:54.009 --> 00:21:56.430 look very similar with pain and imaging changes. 00:21:57.029 --> 00:21:59.349 Then there are non -tumor conditions like myositis 00:21:59.349 --> 00:22:01.950 ossificans, certain metabolic bone diseases, 00:22:02.490 --> 00:22:04.809 osteonecrosis, especially around the hip, or 00:22:04.809 --> 00:22:07.210 synovial proliferative diseases. So how do you 00:22:07.210 --> 00:22:09.990 differentiate, say, an osteoporotic fracture 00:22:09.990 --> 00:22:12.329 from a metastatic one? That's a common dilemma. 00:22:13.009 --> 00:22:15.289 On imaging, a key difference can be the cortical 00:22:15.289 --> 00:22:18.390 bone. In osteoporosis, the cortex might be thin, 00:22:18.450 --> 00:22:21.349 but is usually intact. With metastatic cancer 00:22:21.349 --> 00:22:23.529 causing a fracture, you often see destruction 00:22:23.529 --> 00:22:26.390 of the cortex itself, a moth -eaten or permeative 00:22:26.390 --> 00:22:29.630 look. But clinically, a low energy injury combined 00:22:29.630 --> 00:22:31.869 with any of those SREs we talked about especially, 00:22:32.289 --> 00:22:34.990 that persistent night pain, weight loss, pain 00:22:34.990 --> 00:22:36.890 on weight bearing that should heavily point you 00:22:36.890 --> 00:22:40.009 towards metastatic disease over a simple osteoporotic 00:22:40.009 --> 00:22:43.339 fracture. The presence of those red flag symptoms 00:22:43.339 --> 00:22:45.519 is really key in steering the diagnosis away 00:22:45.519 --> 00:22:48.039 from benign causes. It's about integrating the 00:22:48.039 --> 00:22:50.099 imaging, the labs, and that detailed patient 00:22:50.099 --> 00:22:52.920 history. Hashtag, hashtag prognosis and risk 00:22:52.920 --> 00:22:55.519 assessment. Understanding the likely prognosis 00:22:55.519 --> 00:22:57.960 is just so vital, isn't it? Not just for our 00:22:57.960 --> 00:22:59.700 planning, but for having honest conversations 00:22:59.700 --> 00:23:02.140 with patients. What are the main factors that 00:23:02.140 --> 00:23:03.940 influence survival when cancer has spread to 00:23:03.940 --> 00:23:05.920 the bone? And how do we actually assess that 00:23:05.920 --> 00:23:08.259 critical risk of an impending fracture? Predicting 00:23:08.259 --> 00:23:10.680 outcomes is indeed a crucial part of management. 00:23:11.160 --> 00:23:13.160 It guides everything we do and how we counsel 00:23:13.160 --> 00:23:16.339 patients. Several things strongly influence survival. 00:23:17.140 --> 00:23:19.700 Simply having skeletal metastases is generally 00:23:19.700 --> 00:23:22.359 a poor sign, but having visceral metastases spread 00:23:22.359 --> 00:23:25.000 to organs like the lung, liver, or brain is even 00:23:25.000 --> 00:23:27.859 worse. The number of metastatic sites also matters. 00:23:28.140 --> 00:23:31.000 More sites mean poorer prognosis. Visceral mets 00:23:31.000 --> 00:23:32.940 are often seen as indicating an irreversible 00:23:32.940 --> 00:23:35.640 stage, shifting our focus much more towards palliation. 00:23:35.769 --> 00:23:38.450 The primary tumor type is a massive factor. As 00:23:38.450 --> 00:23:40.950 we saw with those survival stats earlier, lung 00:23:40.950 --> 00:23:43.410 cancer meds might mean months, thyroid cancer 00:23:43.410 --> 00:23:46.089 meds could mean years. That difference drastically 00:23:46.089 --> 00:23:48.529 changes our treatment intensity. Are there specific 00:23:48.529 --> 00:23:51.970 factors within each cancer type? Yes. For breast 00:23:51.970 --> 00:23:54.450 cancer, things like other non -bone meds, the 00:23:54.450 --> 00:23:56.970 time since initial diagnosis, disease -free interval, 00:23:57.450 --> 00:23:59.809 performance status, hormone receptor status, 00:24:00.190 --> 00:24:03.230 age, and tumor grade all play a role. For prostate 00:24:03.230 --> 00:24:06.269 cancer, performance status, non -bone mets, and 00:24:06.269 --> 00:24:08.849 how markers like alkaline phosphatase and PSA 00:24:08.849 --> 00:24:11.750 respond to treatment are key predictors. In multiple 00:24:11.750 --> 00:24:14.569 myeloma, levels of beta -2 microlobulin and C 00:24:14.569 --> 00:24:16.730 -reactive protein are major independent factors. 00:24:17.029 --> 00:24:18.950 High levels mean much shorter survival than low 00:24:18.950 --> 00:24:21.619 levels. Other tumor characteristics matter, too. 00:24:21.619 --> 00:24:23.559 A very large tumor, say over 12 centimeters, 00:24:24.019 --> 00:24:25.880 or a poor response to initial treatment, meaning 00:24:25.880 --> 00:24:28.000 lots of viable tumor left after chemo, predict 00:24:28.000 --> 00:24:29.920 worse survival. Are there tools to help estimate 00:24:29.920 --> 00:24:32.920 survival? Yes. We use predictive models, like 00:24:32.920 --> 00:24:35.579 the Bayesian Belief Network. These take clinical 00:24:35.579 --> 00:24:38.400 data and calculate survival probabilities, often 00:24:38.400 --> 00:24:41.200 at 3 months and 12 months. This is incredibly 00:24:41.200 --> 00:24:43.380 helpful, particularly for surgical decisions. 00:24:43.900 --> 00:24:45.900 If predicted survival is less than 3 months, 00:24:46.279 --> 00:24:48.509 major surgery is generally off the table. The 00:24:48.509 --> 00:24:50.930 focus shifts entirely to comfort care, often 00:24:50.930 --> 00:24:53.589 hospice. If survival is predicted between 3 and 00:24:53.589 --> 00:24:56.250 12 months, we might favor less invasive procedures 00:24:56.250 --> 00:24:58.990 with quicker recovery. But if predicted survival 00:24:58.990 --> 00:25:01.470 is over 12 months, we can consider more durable, 00:25:01.769 --> 00:25:04.049 complex reconstructions aiming for longer -term 00:25:04.049 --> 00:25:07.769 function. One study by Bauer found survival after 00:25:07.769 --> 00:25:10.069 fixing a pathological fracture was often less 00:25:10.069 --> 00:25:12.470 than six months, similar to just getting radiotherapy 00:25:12.470 --> 00:25:14.690 for pain, highlighting how advanced the disease 00:25:14.690 --> 00:25:17.640 often is by then. It's also true that a single 00:25:17.640 --> 00:25:19.839 solitary metastasis generally carries a better 00:25:19.839 --> 00:25:22.480 prognosis than multiple METs, sometimes even 00:25:22.480 --> 00:25:24.079 allowing for treatment with curative intent. 00:25:24.339 --> 00:25:26.559 That's a very practical way to use prognosis 00:25:26.559 --> 00:25:29.079 in decision -making. And preventing those fractures 00:25:29.079 --> 00:25:32.140 is such a key goal, what tools or scoring systems 00:25:32.140 --> 00:25:34.740 do we actually use to predict the bone's mechanical 00:25:34.740 --> 00:25:36.920 strength and fracture risk? And importantly, 00:25:37.200 --> 00:25:39.759 how reliable are they in the real world? Preventing 00:25:39.759 --> 00:25:41.559 pathological fractures is definitely a major 00:25:41.559 --> 00:25:44.160 objective. The most widely used tool for long 00:25:44.160 --> 00:25:46.720 bones is Mural Scoring System. It scores four 00:25:46.720 --> 00:25:49.720 things. The site, upper limb, lower limb, or 00:25:49.720 --> 00:25:52.680 the high -risk peritrochanteric hip region. The 00:25:52.680 --> 00:25:54.900 pain, mild, moderate, or functional weight -bearing 00:25:54.900 --> 00:25:59.079 pain. The lesion type, elastic, mixed, or lytic 00:25:59.079 --> 00:26:01.500 being weaker. And the size related to the bone's 00:26:01.500 --> 00:26:05.140 diameter, less than 13, 1323, or over 23 cortical 00:26:05.140 --> 00:26:06.799 destruction. And how does the score translate 00:26:06.799 --> 00:26:09.880 to risk? A total score of nine suggests a 33 00:26:09.880 --> 00:26:13.529 % fracture risk. A score of 8 suggests 15%, and 00:26:13.529 --> 00:26:16.289 7 or below is about 4%. Generally, a score of 00:26:16.289 --> 00:26:18.710 8 or 9 often triggers a discussion about prophylactic 00:26:18.710 --> 00:26:21.920 fixation surgery to prevent the fracture. However, 00:26:22.140 --> 00:26:24.160 Muriel's score, while common, has significant 00:26:24.160 --> 00:26:27.000 limitations. Its sensitivity is okay, maybe 80 00:26:27.000 --> 00:26:29.680 -90%, but its specificity is often quite poor, 00:26:29.759 --> 00:26:32.759 only 30 -35%. That means it can miss some high 00:26:32.759 --> 00:26:35.240 -risk lesions, but more often it might overpredict 00:26:35.240 --> 00:26:37.420 risk, potentially leading to surgery that wasn't 00:26:37.420 --> 00:26:39.579 strictly necessary. It doesn't fully capture 00:26:39.579 --> 00:26:41.880 the nuances of mechanical stress or overall bone 00:26:41.880 --> 00:26:44.000 quality. So clinical signs are still important? 00:26:44.539 --> 00:26:46.500 Absolutely paramount, often more important than 00:26:46.500 --> 00:26:49.680 the score. Excessive pain, especially pain that 00:26:49.680 --> 00:26:51.799 gets worse with weight bearing or comes on suddenly, 00:26:52.140 --> 00:26:54.359 is a huge red flag for an impending fracture. 00:26:54.859 --> 00:26:57.339 And a classic sign for an impending hip fracture 00:26:57.339 --> 00:26:59.640 is seeing an evulsion of the lesser trochanter 00:26:59.640 --> 00:27:02.319 on x -ray. That little piece of bone pulls off 00:27:02.319 --> 00:27:05.220 because the underlying bone is so weak. We also 00:27:05.220 --> 00:27:06.980 have to remember x -rays aren't sensitive enough 00:27:06.980 --> 00:27:09.859 early on. You need significant bone loss to see 00:27:09.859 --> 00:27:12.819 it. The patient's symptoms are key. There's a 00:27:12.819 --> 00:27:15.000 newer and importantly more accurate method called 00:27:15.000 --> 00:27:19.269 CT rigidity analysis, or CTRA. It uses CT scan 00:27:19.269 --> 00:27:21.630 data to directly measure bone density and geometry 00:27:21.630 --> 00:27:24.130 at the weakest point. It estimates the bone's 00:27:24.130 --> 00:27:26.309 resistance to bending, twisting, and axial loading. 00:27:26.670 --> 00:27:28.470 How does that compare? It compares the results 00:27:28.470 --> 00:27:30.990 to normal bone data, matched for gender and size. 00:27:31.450 --> 00:27:33.470 If the calculated rigidity is reduced by more 00:27:33.470 --> 00:27:36.329 than 35%, that indicates a significant fracture 00:27:36.329 --> 00:27:39.710 risk. Studies show CTRA has better sensitivity, 00:27:39.930 --> 00:27:41.930 specificity, positive and negative predictive 00:27:41.930 --> 00:27:44.720 value than Merrill's score. It's a more objective 00:27:44.720 --> 00:27:47.039 and reliable tool, though it does need specialized 00:27:47.039 --> 00:27:49.880 software and expertise to perform. Hashtag comprehensive 00:27:49.880 --> 00:27:52.299 management strategies. It's so clear that managing 00:27:52.299 --> 00:27:55.519 this is incredibly complex, needing careful coordination. 00:27:56.240 --> 00:27:58.839 How do we structure the overall therapeutic approach? 00:27:59.259 --> 00:28:02.400 And why is that multidisciplinary team, the MDT, 00:28:02.559 --> 00:28:04.940 just so fundamental to getting the best outcomes, 00:28:05.220 --> 00:28:07.779 especially when balancing survival and quality 00:28:07.779 --> 00:28:10.480 of life? You've hit the absolute core principle. 00:28:11.180 --> 00:28:13.839 Managing bone metastasis demands an interprofessional, 00:28:14.000 --> 00:28:16.599 multidisciplinary approach. It's just too complex 00:28:16.599 --> 00:28:19.299 for one specialist alone. The team usually involves 00:28:19.299 --> 00:28:22.099 the orthopedic surgeon, often an orthopedic oncologist, 00:28:22.660 --> 00:28:25.359 radiologists interpreting the scans, radiation 00:28:25.359 --> 00:28:28.099 oncologists, medical oncologists managing the 00:28:28.099 --> 00:28:30.400 systemic cancer treatment. But crucially, it 00:28:30.400 --> 00:28:33.039 also includes pain management specialists, social 00:28:33.039 --> 00:28:35.680 workers, and often hospice nurses, especially 00:28:35.680 --> 00:28:37.380 thinking about the patient's whole journey and 00:28:37.380 --> 00:28:39.250 quality of life. So what are the main goals of 00:28:39.250 --> 00:28:41.849 this team? The overarching goals are really focused 00:28:41.849 --> 00:28:43.890 on preserving the patient's quality of life, 00:28:44.309 --> 00:28:46.609 controlling their pain effectively, minimizing 00:28:46.609 --> 00:28:49.410 those skeletal related events, and achieving 00:28:49.410 --> 00:28:52.269 local tumor control where we can. Every decision 00:28:52.269 --> 00:28:54.930 weighs up multiple factors. How widespread is 00:28:54.930 --> 00:28:57.130 the disease? What's the patient's overall fitness, 00:28:57.309 --> 00:28:59.470 their performance status? What's the assessed 00:28:59.470 --> 00:29:02.289 fracture risk? And what are the potential side 00:29:02.289 --> 00:29:05.369 effects of any treatment we propose? The focus 00:29:05.369 --> 00:29:07.670 has to be ensuring the patient has a decent quality 00:29:07.670 --> 00:29:10.450 of life. Many are frail, many have a terminal 00:29:10.450 --> 00:29:13.190 diagnosis. So we have to be careful to avoid 00:29:13.190 --> 00:29:16.230 unnecessary tests of procedures that just add 00:29:16.230 --> 00:29:19.230 burden. For many, comfort care or hospice becomes 00:29:19.230 --> 00:29:21.329 the most appropriate and compassionate path, 00:29:21.910 --> 00:29:23.809 especially given that the prognosis for widespread 00:29:23.809 --> 00:29:26.289 bone mets is often limited historically four 00:29:26.289 --> 00:29:28.960 to 12 months. Although, as we've touched on, 00:29:29.200 --> 00:29:30.660 new systemic treatments are starting to push 00:29:30.660 --> 00:29:32.640 that time frame out for some people, which brings 00:29:32.640 --> 00:29:34.619 its own set of challenges for longer term management. 00:29:34.920 --> 00:29:36.579 That collaborative approach sounds essential. 00:29:37.339 --> 00:29:39.460 Let's break down the non -surgical options within 00:29:39.460 --> 00:29:42.440 that MDT framework. What are the main medical 00:29:42.440 --> 00:29:45.019 therapies and radiation techniques we use? How 00:29:45.019 --> 00:29:47.119 do they fit into the strategy for pain relief 00:29:47.119 --> 00:29:50.160 and controlling the disease? Non -surgical management 00:29:50.160 --> 00:29:52.200 is a huge part of the picture, especially as 00:29:52.200 --> 00:29:54.420 palliation and quality of life are often the 00:29:54.420 --> 00:29:57.769 primary goals. Pain control analgesia is obviously 00:29:57.769 --> 00:30:00.269 a major focus. We usually start with NSAIDs, 00:30:00.450 --> 00:30:02.690 then titrate up or add narcotics like opioids 00:30:02.690 --> 00:30:06.309 as needed to keep the patient comfortable. Glucocorticoids, 00:30:06.650 --> 00:30:08.890 steroids can sometimes help with pain, maybe 00:30:08.890 --> 00:30:11.430 by reducing swelling around the tumor, but their 00:30:11.430 --> 00:30:13.890 use needs careful MDT discussion due to potential 00:30:13.890 --> 00:30:16.829 side effects or impact on biopsy results. Bone 00:30:16.829 --> 00:30:19.559 modifying agents are crucial. These are the osteoclast 00:30:19.559 --> 00:30:22.299 inhibitors. They significantly reduce SREs and 00:30:22.299 --> 00:30:24.799 help with bone pain, decreasing overall morbidity. 00:30:25.279 --> 00:30:27.400 The two main classes are bisphosphonates like 00:30:27.400 --> 00:30:30.259 pomidrinate, zolderonic acid, and dinosunab. 00:30:30.440 --> 00:30:32.759 How they work differently. Bisphosphonates reduce 00:30:32.759 --> 00:30:34.920 bone breakdown and associated hypercalcemia. 00:30:35.200 --> 00:30:38.799 They cut SRE risk by about 30 -40%. A key potential 00:30:38.799 --> 00:30:41.559 side effect is osteonecrosis of the jaw, so dental 00:30:41.559 --> 00:30:44.220 checks are important. Some also have direct anti 00:30:44.220 --> 00:30:47.410 -tumor effects. Dinosumab is a monoclonal antibody 00:30:47.410 --> 00:30:50.190 targeting Aran -KL, that key signaling protein. 00:30:50.789 --> 00:30:53.029 It's actually been shown to be superior to zoledronic 00:30:53.029 --> 00:30:56.710 acid in preventing SREs. It directly blocks osteoclast 00:30:56.710 --> 00:31:00.410 formation. A big advantage is it's given subcutaneously 00:31:00.410 --> 00:31:02.630 and isn't cleared by the kidneys, making it a 00:31:02.630 --> 00:31:04.589 good option for patients with kidney problems. 00:31:05.190 --> 00:31:07.829 Radiation therapy, RT, is a cornerstone, especially 00:31:07.829 --> 00:31:10.599 for paneliation. Local field radiation is standard 00:31:10.599 --> 00:31:13.220 for painful spots. It reduces pain in 50 -80 00:31:13.220 --> 00:31:15.980 % of patients, complete relief in maybe 30%. 00:31:15.980 --> 00:31:18.079 We also use it after surgery sometimes to consolidate 00:31:18.079 --> 00:31:20.779 healing. Studies show a single dose, like eight 00:31:20.779 --> 00:31:23.279 gray, is often just as good for pain relief as 00:31:23.279 --> 00:31:25.359 longer courses, say 30 gray and 10 fractions, 00:31:25.779 --> 00:31:27.400 though the single dose might need repeating more 00:31:27.400 --> 00:31:29.440 often. Are there more targeted radiation options? 00:31:29.900 --> 00:31:33.640 Yes. Stereotactic Body Radiation Therapy, SBRT, 00:31:34.140 --> 00:31:36.759 delivers a very high -focused dose while sparing 00:31:36.759 --> 00:31:39.769 surrounding tissues. It might be used for specific 00:31:39.769 --> 00:31:41.990 spinal meds, from tumors usually resistant to 00:31:41.990 --> 00:31:44.690 standard radiation, or sometimes for oligometastatic 00:31:44.690 --> 00:31:47.470 disease. For very widespread disease, hemi -body 00:31:47.470 --> 00:31:49.890 irradiation, treating half the body, is an option, 00:31:49.930 --> 00:31:52.690 but used less now. And then there's bone -targeted 00:31:52.690 --> 00:31:55.109 radiopharmaceutical therapy. These are radioactive 00:31:55.109 --> 00:31:58.549 drugs like Strontium -89 or Radium -223 that 00:31:58.549 --> 00:32:00.910 specifically target bone, delivering radiation 00:32:00.910 --> 00:32:03.710 diffusely. Good for widespread pain, especially 00:32:03.710 --> 00:32:05.650 from plastic meds like in prostate or breast 00:32:05.650 --> 00:32:08.450 cancer, or if other treatments fail. Systemic 00:32:08.450 --> 00:32:10.710 chemotherapy, of course, plays a role if the 00:32:10.710 --> 00:32:13.269 primary cancer is responsive. Shrinking the primary 00:32:13.269 --> 00:32:15.309 and other meds can reduce overall disease burden 00:32:15.309 --> 00:32:18.410 and help with pain indirectly. And finally, local 00:32:18.410 --> 00:32:20.390 ablation techniques. These are for persistent 00:32:20.390 --> 00:32:22.890 or recurrent pain after radiation. Things like 00:32:22.890 --> 00:32:25.710 radiofrequency ablation, RFA, using heat, or 00:32:25.710 --> 00:32:28.150 cryoablation using freezing. Focused ultrasound, 00:32:28.289 --> 00:32:31.130 FUS, is newer. Cementoplasty injecting bone cement. 00:32:31.509 --> 00:32:33.769 Often PMMA is vital, especially for pelvic lesions 00:32:33.769 --> 00:32:35.829 or other lytic defects. It provides immediate 00:32:35.829 --> 00:32:38.589 stability. relieving pain and improving function 00:32:38.589 --> 00:32:41.990 in about 80 % of cases. And for very vascular 00:32:41.990 --> 00:32:44.369 tumors like kidney or thyroid meds, preoperative 00:32:44.369 --> 00:32:46.950 angiomyelization can block blood supply, reducing 00:32:46.950 --> 00:32:48.710 bleeding during surgery and potentially enhancing 00:32:48.710 --> 00:32:51.329 pain relief. That's a really comprehensive non 00:32:51.329 --> 00:32:54.289 -surgical toolkit. Now, for us in orthopedics, 00:32:54.309 --> 00:32:57.109 surgery is often critical, but the goals are 00:32:57.109 --> 00:33:00.180 different from standard trauma surgery. What 00:33:00.180 --> 00:33:02.920 are the main aims of surgery here? What principles 00:33:02.920 --> 00:33:05.700 guide these operations? And how do the approaches 00:33:05.700 --> 00:33:08.460 vary depending on which limb or part of the limb 00:33:08.460 --> 00:33:11.400 is affected? Surgery is indeed a vital component, 00:33:11.460 --> 00:33:13.660 and you're right, the mindset is different. The 00:33:13.660 --> 00:33:16.619 main goals are quite clear. treat or ideally 00:33:16.619 --> 00:33:19.980 prevent broken bones, relieve severe pain, reduce 00:33:19.980 --> 00:33:22.880 reliance on heavy pain meds, restore skeletal 00:33:22.880 --> 00:33:25.339 strength and stability, and ultimately help the 00:33:25.339 --> 00:33:27.460 patient regain function and independence for 00:33:27.460 --> 00:33:30.160 daily activities. A really key principle is that 00:33:30.160 --> 00:33:32.500 prophylactic stabilization, fixing the bone before 00:33:32.500 --> 00:33:35.259 it breaks, leads to significantly better outcomes 00:33:35.259 --> 00:33:37.900 than operating after a fracture. Patients have 00:33:37.900 --> 00:33:40.160 shorter hospital stays or more likely to go home, 00:33:40.319 --> 00:33:42.880 get back to activity faster, have fewer complications, 00:33:43.160 --> 00:33:44.960 and may even live longer because they avoid the 00:33:44.960 --> 00:33:47.319 major physiological hit of a fracture. It allows 00:33:47.319 --> 00:33:49.380 us to coordinate surgery better with their systemic 00:33:49.380 --> 00:33:51.359 treatment, too. What are the core surgical principles, 00:33:51.500 --> 00:33:54.519 then? First, that golden rule again, biopsy first. 00:33:54.920 --> 00:33:57.079 Complete workup before surgery, especially for 00:33:57.079 --> 00:33:59.140 pathological fractures. Know what you're treating. 00:33:59.839 --> 00:34:02.299 Second, our fixation doesn't rely on bone healing. 00:34:02.460 --> 00:34:05.680 These lesions rarely heal. So we use strong hardware 00:34:05.680 --> 00:34:08.639 plates, rods, nails, screws, often combined with 00:34:08.639 --> 00:34:11.579 bone cement, PMMA, for immediate stability and 00:34:11.579 --> 00:34:13.800 strength. PMMA lets patients bear weight sooner 00:34:13.800 --> 00:34:15.780 and approves pain relief by filling the defect. 00:34:16.539 --> 00:34:18.579 Third, a general rule is to protect the entire 00:34:18.579 --> 00:34:21.420 bone. If you fix just the lesion, it might fail 00:34:21.420 --> 00:34:24.360 above or below due to disease progression. So 00:34:24.360 --> 00:34:26.860 we often use long, intramedullary nails that 00:34:26.860 --> 00:34:29.539 span the whole bone. Fourth, post -operative 00:34:29.539 --> 00:34:31.460 radiation is recommended for almost all patients 00:34:31.460 --> 00:34:33.739 starting two, three weeks after surgery, covering 00:34:33.739 --> 00:34:35.820 a whole surgical field and implant. It helps 00:34:35.820 --> 00:34:38.619 mop up any remaining microscopic disease, unless, 00:34:38.639 --> 00:34:40.559 of course, the patient is very near end of life 00:34:40.559 --> 00:34:43.039 or had previous radiation there. And finally, 00:34:43.099 --> 00:34:45.280 for solitary lesions, if the patient's prognosis 00:34:45.280 --> 00:34:47.659 allows, we might consider more aggressive surgery 00:34:47.659 --> 00:34:50.340 like wide excision aiming for local cure, though 00:34:50.340 --> 00:34:52.179 that's less common than palliative stabilization. 00:34:52.380 --> 00:34:54.699 That framework makes a lot of sense. Now, the 00:34:54.699 --> 00:34:57.829 limbs have very different anatomy. Can you walk 00:34:57.829 --> 00:35:00.269 us through the tailored surgical strategies for 00:35:00.269 --> 00:35:02.389 different areas, the pelvis, the lower limb, 00:35:02.469 --> 00:35:04.409 the upper limb, and maybe touch on the spine? 00:35:04.690 --> 00:35:06.630 Absolutely. The approach has to be adapted to 00:35:06.630 --> 00:35:08.969 the specific site, the extent of bone loss, and 00:35:08.969 --> 00:35:10.809 the patient's prognosis and functional needs. 00:35:11.329 --> 00:35:13.210 Let's start with the pelvis. We often use the 00:35:13.210 --> 00:35:16.469 Anakin classification zones 1, 2, and 3. Zones 00:35:16.469 --> 00:35:18.750 1 and 3 are generally non -weight -bearing, but 00:35:18.750 --> 00:35:21.469 zone 2, the acetopelomyscium area, is critical 00:35:21.469 --> 00:35:24.269 for weight -bearing. Lesions here, or involving 00:35:24.269 --> 00:35:26.840 adjacent zones, are problematic. Treatment might 00:35:26.840 --> 00:35:28.800 range from curatage and cementing for contained 00:35:28.800 --> 00:35:31.340 lesions to major reconstructions for large defects 00:35:31.340 --> 00:35:34.360 using custom implants, saddle processes, or even 00:35:34.360 --> 00:35:36.780 total hip replacements reinforced with pins and 00:35:36.780 --> 00:35:38.559 cement the Harrington technique if bone stock 00:35:38.559 --> 00:35:41.519 is poor. The goal is always to restore stability 00:35:41.519 --> 00:35:44.579 for sitting and potentially walking. Moving to 00:35:44.579 --> 00:35:46.739 the lower limb, the most common site, femur accounts 00:35:46.739 --> 00:35:49.559 for 75%. Pain and ability to walk are the main 00:35:49.559 --> 00:35:53.079 concerns. In the proximal femur, hip area, impending 00:35:53.079 --> 00:35:55.860 or actual fractures almost never heal. The standard 00:35:55.860 --> 00:35:58.179 treatment is usually a bipolar hemiarthroplasty, 00:35:58.280 --> 00:36:00.440 replacing the ball part of the joint, often with 00:36:00.440 --> 00:36:03.119 a long stem to bypass a lesion. If the socket, 00:36:03.219 --> 00:36:05.119 as a tabulum, is also involved, then a total 00:36:05.119 --> 00:36:07.059 hip replacement. For very large lesions here, 00:36:07.219 --> 00:36:09.639 sometimes an endoprosthesis, replacing a whole 00:36:09.639 --> 00:36:11.539 segment of bone, gives the best stability and 00:36:11.539 --> 00:36:14.079 allows early weight -bearing. For the femoral 00:36:14.079 --> 00:36:16.460 shaft, the best option is usually a load -sharing 00:36:16.460 --> 00:36:19.840 intramedullary nail, locked in place, often with 00:36:19.840 --> 00:36:22.539 cement augmentation to fill defects. It provides 00:36:22.539 --> 00:36:25.800 strong internal support. Distal fever near the 00:36:25.800 --> 00:36:28.300 knee lesions are tricky, often poor bone quality, 00:36:28.340 --> 00:36:30.960 multiple fragments. For smaller lesions, maybe 00:36:30.960 --> 00:36:33.420 plate fixation with cement. But for extensive 00:36:33.420 --> 00:36:35.119 destruction, especially involving the joint, 00:36:35.539 --> 00:36:37.719 a composite total knee replacement, essentially 00:36:37.719 --> 00:36:40.639 a large tumor prosthesis might be needed. The 00:36:40.639 --> 00:36:43.300 tibia, shin bone, is less common. Upper tibia 00:36:43.300 --> 00:36:45.280 is managed similarly to distal femur cement. 00:36:45.440 --> 00:36:47.940 Plates may be replacement. Tivial shaft usually 00:36:47.940 --> 00:36:50.760 gets a metal rod. Distal tibia often plates and 00:36:50.760 --> 00:36:52.619 screws with cement. The foot is very rare, less 00:36:52.619 --> 00:36:56.039 than 1%. Usually from lung, kidney, colon. Treatment 00:36:56.039 --> 00:36:58.340 is very individual radiation, orthotics, maybe 00:36:58.340 --> 00:37:00.860 limited surgery, sometimes even amputation of 00:37:00.860 --> 00:37:03.139 a toe for pain control. And the upper limb? The 00:37:03.139 --> 00:37:05.579 upper limb accounts for maybe 20 % of cases, 00:37:05.760 --> 00:37:08.320 half of those in the humerus. It's less mechanically 00:37:08.320 --> 00:37:10.119 stressed than the leg, so sometimes humeral mets 00:37:10.119 --> 00:37:12.400 can be managed non -operatively with just radiation 00:37:12.400 --> 00:37:15.579 if retracture risk is low. But they can severely 00:37:15.579 --> 00:37:18.320 impair function. For the upper humerus, large 00:37:18.320 --> 00:37:20.320 tumors might need a prosthetic replacement of 00:37:20.320 --> 00:37:23.059 the top part of the bone. These are complex ops 00:37:23.059 --> 00:37:25.119 and function can be limited because the rotator 00:37:25.119 --> 00:37:27.739 cuff often needs to be detached and reattached. 00:37:28.300 --> 00:37:30.320 Humeral shaft tumors are usually best treated 00:37:30.320 --> 00:37:33.119 with intermedullary rods, often with cement, 00:37:33.599 --> 00:37:35.869 spanning the whole bone for stability. Plates 00:37:35.869 --> 00:37:37.889 are an option, but left common for the shaft. 00:37:38.389 --> 00:37:40.329 Near the elbow, flexible nails can work while 00:37:40.329 --> 00:37:42.530 preserving the joint. If the tumor goes into 00:37:42.530 --> 00:37:44.789 the joint, an elbow replacement might be needed. 00:37:45.269 --> 00:37:48.369 Forearm and hand mets are rare. Lung, breast, 00:37:48.429 --> 00:37:50.590 renal are common primaries, usually treated with 00:37:50.590 --> 00:37:53.590 rods, plates, or bracing. And the scapula, shoulder 00:37:53.590 --> 00:37:55.969 blade, depending on extent, might need partial 00:37:55.969 --> 00:37:59.030 or total scapulaectomy. And briefly, the spine. 00:37:59.369 --> 00:38:01.869 The spine is the most common site overall, but 00:38:01.869 --> 00:38:03.710 surgery is actually less common than you might 00:38:03.710 --> 00:38:06.699 think. Radiation is preferred if there's pain 00:38:06.699 --> 00:38:10.099 but no nerve damage or major instability. Surgeries 00:38:10.099 --> 00:38:12.679 mainly for neurological deficits like cord compression, 00:38:13.019 --> 00:38:16.420 ongoing pain after RT, or instability. Minimally 00:38:16.420 --> 00:38:18.980 invasive techniques like vertebroplasty, cement 00:38:18.980 --> 00:38:21.699 injection, and kyphoplasty, balloon inflation, 00:38:21.880 --> 00:38:25.079 then cement, are widely used now, often off -label, 00:38:25.420 --> 00:38:28.139 at major centers to stabilize fractures and relieve 00:38:28.139 --> 00:38:30.610 pain effectively in selected patients. That's 00:38:30.610 --> 00:38:32.630 incredibly detailed, thank you. It really highlights 00:38:32.630 --> 00:38:35.130 the bespoke nature of these surgeries. But with 00:38:35.130 --> 00:38:37.590 such complex operations, often in patients who 00:38:37.590 --> 00:38:40.210 are already quite unwell, what are the potential 00:38:40.210 --> 00:38:42.510 computations? And how much does the patient's 00:38:42.510 --> 00:38:44.630 overall health weigh into the decision to even 00:38:44.630 --> 00:38:47.349 proceed with surgery? That's a critical consideration. 00:38:47.809 --> 00:38:49.710 Surgical treatment for metastatic bone disease 00:38:49.710 --> 00:38:52.510 is definitely complex, and it inherently carries 00:38:52.510 --> 00:38:55.150 higher risks than routine orthopedic surgery. 00:38:55.480 --> 00:38:57.739 This is largely because the patients themselves 00:38:57.739 --> 00:38:59.760 are often less healthy. They might have multiple 00:38:59.760 --> 00:39:02.159 other health issues, be weakened by cancer treatments, 00:39:02.579 --> 00:39:05.119 may be immunocompromised, generally more frail. 00:39:05.239 --> 00:39:08.480 So standard risks are magnified. Exactly. They're 00:39:08.480 --> 00:39:10.659 at increased risk of common surgical complications, 00:39:10.780 --> 00:39:12.980 which can be much more serious for them. Things 00:39:12.980 --> 00:39:16.099 like persistent pain, significant bleeding during 00:39:16.099 --> 00:39:18.739 or after surgery, infection, which is particularly 00:39:18.739 --> 00:39:20.920 dangerous if they're immunocompromised and damage 00:39:20.920 --> 00:39:23.420 to nearby nerves or blood vessels, potentially 00:39:23.420 --> 00:39:27.119 causing numbness or even paralysis. Beyond those 00:39:27.119 --> 00:39:29.059 immediate risks, there's always the chance of 00:39:29.059 --> 00:39:31.340 the tumor recurring locally or the underlying 00:39:31.340 --> 00:39:33.840 cancer progressing elsewhere. And tragically, 00:39:34.039 --> 00:39:36.300 sometimes patients can die from surgical complications 00:39:36.300 --> 00:39:38.699 or simply due to the rapid progression of their 00:39:38.699 --> 00:39:41.480 advanced cancer. Given all these potential downsides, 00:39:41.800 --> 00:39:44.260 the decision to operate is never taken lightly. 00:39:44.719 --> 00:39:47.179 It absolutely has to be a very careful, very 00:39:47.179 --> 00:39:49.659 informed cooperative discussion. It involves 00:39:49.659 --> 00:39:51.980 the patient, their family, the surgeon, the oncologist, 00:39:52.199 --> 00:39:54.780 the whole team. We have to meticulously weigh 00:39:54.780 --> 00:39:57.059 the potential benefits, pain relief, improved 00:39:57.059 --> 00:39:59.179 function, better quality of life against these 00:39:59.179 --> 00:40:02.199 very real and significant risks. The final decision 00:40:02.199 --> 00:40:04.019 must align with the patient's overall goals, 00:40:04.300 --> 00:40:06.599 their wishes and their prognosis, focusing on 00:40:06.599 --> 00:40:09.599 what truly matters most to them. Hashtag tag 00:40:09.599 --> 00:40:11.599 tag enhancing health care team outcome. So pulling 00:40:11.599 --> 00:40:14.000 it all together, then, what are the key principles 00:40:14.000 --> 00:40:16.260 for really enhancing health care team outcomes 00:40:16.260 --> 00:40:19.199 when managing metastatic bone disease, especially 00:40:19.199 --> 00:40:21.260 thinking about the patient's quality of life 00:40:21.260 --> 00:40:23.599 across their entire journey from the initial 00:40:23.599 --> 00:40:26.320 diagnosis right through to end of life care? 00:40:26.380 --> 00:40:29.139 To really optimize outcomes, the absolute bedrock 00:40:29.139 --> 00:40:31.400 principle, as we've said throughout. is that 00:40:31.400 --> 00:40:33.840 interprofessional, multidisciplinary approach. 00:40:34.219 --> 00:40:36.699 It's got to be a team effort focused consistently 00:40:36.699 --> 00:40:39.139 on preserving quality of life, controlling pain, 00:40:39.320 --> 00:40:41.880 minimizing those SREs, and achieving local tumor 00:40:41.880 --> 00:40:44.519 control where appropriate and feasible. It's 00:40:44.519 --> 00:40:46.739 about pooling expertise for the patient's benefit. 00:40:47.219 --> 00:40:49.619 When we devise that initial treatment plan, it's 00:40:49.619 --> 00:40:52.179 critical to consider the whole picture, all those 00:40:52.179 --> 00:40:54.780 holistic patient factors. How far has the disease 00:40:54.780 --> 00:40:56.920 spread? What's their functional capacity, their 00:40:56.920 --> 00:40:59.519 performance status? What's the real risk of fracture? 00:40:59.769 --> 00:41:01.969 And what are the potential burdens and side effects 00:41:01.969 --> 00:41:04.130 of different treatments? We're constantly balancing 00:41:04.130 --> 00:41:06.170 aggressive intervention against purely palliative 00:41:06.170 --> 00:41:08.909 goals, and that balance can shift as the patient's 00:41:08.909 --> 00:41:10.849 condition changes or their priorities evolve. 00:41:11.289 --> 00:41:13.210 Pain management is a continuous thread throughout, 00:41:13.789 --> 00:41:16.230 starting with simpler analgesics, titrating up, 00:41:16.389 --> 00:41:19.190 adding opioids, maybe using adjuvant drugs or 00:41:19.190 --> 00:41:21.090 referring to pain specialists for nerve blocks 00:41:21.090 --> 00:41:23.630 or other interventions. Keeping the patient comfortable 00:41:23.630 --> 00:41:26.429 is paramount. And crucially, we always need to 00:41:26.429 --> 00:41:28.869 practice compassionate care. Recognize that many 00:41:28.869 --> 00:41:31.349 patients are frail. Many are facing the end of 00:41:31.349 --> 00:41:34.590 their life. Unnecessary tests, burdens of procedures, 00:41:34.769 --> 00:41:37.289 these should be avoided. The focus might need 00:41:37.289 --> 00:41:39.349 to shift entirely towards maximizing comfort, 00:41:39.610 --> 00:41:42.929 dignity, and quality time. That's where key support 00:41:42.929 --> 00:41:45.610 roles become so important. Having a dedicated 00:41:45.610 --> 00:41:47.989 pain specialist involved, a social worker to 00:41:47.989 --> 00:41:49.989 help navigate practical and emotional challenges, 00:41:50.449 --> 00:41:53.090 and ideally, hospice or palliative care nurses 00:41:53.090 --> 00:41:55.989 integrated early on. They are all essential to 00:41:55.989 --> 00:41:57.849 ensure the patient maintains the best possible 00:41:57.849 --> 00:42:00.409 quality of life throughout their illness, providing 00:42:00.409 --> 00:42:02.630 both medical and vital psychosocial support. 00:42:03.510 --> 00:42:05.989 And while historically prognosis was often limited, 00:42:06.449 --> 00:42:07.989 we do need to remember that for some patients, 00:42:08.409 --> 00:42:10.710 thanks to better systemic therapies, we are looking 00:42:10.710 --> 00:42:13.320 at longer timeframes now. So, while quality of 00:42:13.320 --> 00:42:15.719 life remains central, planning for durable solutions 00:42:15.719 --> 00:42:18.000 and longer -term function is becoming increasingly 00:42:18.000 --> 00:42:20.300 relevant for a subset of these patients. Hashtags, 00:42:20.440 --> 00:42:22.079 hashtags, outro, what? Okay, let's just try and 00:42:22.079 --> 00:42:25.860 unpack all of that. What an incredibly insightful 00:42:25.860 --> 00:42:30.659 deep dive into the very complex world of extremity, 00:42:30.679 --> 00:42:33.199 skeletal, and metastasis. We've really covered 00:42:33.199 --> 00:42:35.059 the whole spectrum, haven't we, from the, well, 00:42:35.239 --> 00:42:37.360 the insidious ways it spreads and those awful 00:42:37.360 --> 00:42:39.980 SREs through the complex diagnostic pathways 00:42:39.980 --> 00:42:42.539 right up to the highly individual. but always 00:42:42.539 --> 00:42:45.260 patient -focused treatment strategies. And what's 00:42:45.260 --> 00:42:47.119 really striking, I think, for us as clinicians 00:42:47.119 --> 00:42:49.199 is seeing how things are constantly evolving. 00:42:49.659 --> 00:42:51.760 The advancements in both medical and surgical 00:42:51.760 --> 00:42:54.199 approaches mean we genuinely have better options 00:42:54.199 --> 00:42:56.400 now for pain control and for maintaining function 00:42:56.400 --> 00:42:58.900 for longer. But as you stressed, it all comes 00:42:58.900 --> 00:43:01.119 back to that collaborative, multidisciplinary 00:43:01.119 --> 00:43:03.639 teamwork, tailoring everything to the individual 00:43:03.639 --> 00:43:06.179 patient, their unique prognosis, their needs, 00:43:06.280 --> 00:43:08.500 their goals. So what does this mean for you, 00:43:08.619 --> 00:43:10.400 our listeners in the medical profession? I think 00:43:10.400 --> 00:43:12.320 it really highlights just how vital it is to 00:43:12.320 --> 00:43:14.320 understand these nuances. It allows for more 00:43:14.320 --> 00:43:16.539 precise interventions, more realistic conversations 00:43:16.539 --> 00:43:18.619 with patients, and ultimately, truly patient 00:43:18.619 --> 00:43:21.599 -centered care. Because the goal always, at every 00:43:21.599 --> 00:43:23.980 single stage, has got to be maximizing that precious 00:43:23.980 --> 00:43:26.480 quality of life. And it does raise a really important 00:43:26.480 --> 00:43:29.059 question. for the future. As our systemic therapies 00:43:29.059 --> 00:43:31.760 get better and better, extending life for patients 00:43:31.760 --> 00:43:34.380 with metastatic disease, sometimes turning it 00:43:34.380 --> 00:43:37.420 into more of a chronic condition, how will we 00:43:37.420 --> 00:43:39.800 in orthopedics need to adapt our management? 00:43:40.300 --> 00:43:43.019 How do we provide even more durable, functionally 00:43:43.019 --> 00:43:45.599 robust, and perhaps less burdensome solutions 00:43:45.599 --> 00:43:48.019 for people living longer, sometimes for years, 00:43:48.320 --> 00:43:51.059 with bone metastasis? That's a challenge, I think, 00:43:51.119 --> 00:43:53.039 that will really shape our practice going forward. 00:43:53.289 --> 00:43:55.969 If you found this deep dive valuable today, please 00:43:55.969 --> 00:43:58.090 do take just a moment to rate and share it with 00:43:58.090 --> 00:44:00.269 a colleague who you think might also benefit 00:44:00.269 --> 00:44:01.070 from these insights.